National Research Council of Canada supports development of 4 COVID-19 therapeutic candidates

December 18, 2020
Bold Therapeutics Inc.

Investment of $9 million will help ensure Canadian innovators have the tools needed to develop treatments today and into the future December 18, 2020 – Ottawa, Ontario – National Research Council of Canada The Government of Canada is aggressively pursuing the purchase and development of COVID-19 treatments and related supplies to protect Canadians and is … Continue reading National Research Council of Canada supports development of 4 COVID-19 therapeutic candidates

Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

Qu Biologics Inc.

Vancouver, British Columbia – December 18, 2020 – Qu Biologics Inc., a private clinical-stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is receiving advisory services and research and development funding from the National Research Council of Canada Industrial Research … Continue reading Qu Biologics Receives Funding for COVID-19 Prevention/Treatment Research with Qu’s Novel Immunotherapy Platform

Vancouver Start-Up’s Successful COVID-19 Transition Aided by Student Wage Subsidies

December 17, 2020
BioTalent Canada

Four years ago, British Columbia high-school-student-turned-founder-and-chief-innovative-officer Mateo Pekic invented the core technology that would become Vancouver 3D printing company 3DQue. He wasn’t legally old enough to be an officer in a company. So, he reached out to Steph Sharp, a classmate’s mom and a veteran of the start-up landscape. “When Mateo decided to commercialize his technology, … Continue reading Vancouver Start-Up’s Successful COVID-19 Transition Aided by Student Wage Subsidies

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Aurinia Pharmaceuticals Inc.

Aurinia to receive $50 million U.S. upfront payment in addition to up to $50 million U.S. in regulatory and reimbursement milestone payments Agreement includes royalties of up to 20 percent on net sales payable to Aurinia VICTORIA, British Columbia & ROCKVILLE, Md.–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today … Continue reading Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

Labour Report sheds light on where Graduates find work in Bio-Economy

BioTalent Canada

OTTAWA, December 16, 2020 – BioTalent Canada today released new findings from its most recent bio-economy Labour Market Information (LMI) study. This new brief—Academic Bonds: Examining the ties that bind STEM grads to their schools—reveals that few biotech graduates choose to relocate to find employment, with most seeking employment close to where they studied. There are several … Continue reading Labour Report sheds light on where Graduates find work in Bio-Economy

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

December 15, 2020
Aurinia Pharmaceuticals Inc.

State-of-the-Art Monoplant Will Provide Cost and Production Efficiency and Secure Active Pharmaceutical Ingredient (API) Supply for Future Commercial Demand – VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) (“Lonza“) today announced they have expanded their exclusive manufacturing relationship. The parties entered into a collaborative agreement … Continue reading Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Zymeworks Inc.

VANCOUVER, British Columbia–(BUSINESS WIRE)– Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021. The presentations highlight updated clinical data for the HER2‑targeted bispecific antibody, … Continue reading Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

CHINOOK THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH MOREHOUSE SCHOOL OF MEDICINE FOR DEVELOPMENT OF THERAPIES IN KIDNEY DISEASES DISPROPORTIONATELY AFFECTING AFRICAN AMERICANS AND UNDERSERVED COMMUNITIES

Chinook Therapeutics Inc.

VANCOUVER, British Columbia and SEATTLE, Dec. 08, 2020 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that it has entered into a license agreement with Morehouse School of Medicine for certain patents supporting the development of therapeutics in kidney diseases that disproportionately affect people … Continue reading CHINOOK THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH MOREHOUSE SCHOOL OF MEDICINE FOR DEVELOPMENT OF THERAPIES IN KIDNEY DISEASES DISPROPORTIONATELY AFFECTING AFRICAN AMERICANS AND UNDERSERVED COMMUNITIES

adMare Communique

December 11, 2020
adMare BioInnovations

adMare is proud to be an early adopter of the Government’s 50 – 30 Challenge to accelerate diversity and inclusion in our workforce at the senior leadership level. To build a stronger life sciences industry across Canada, we know that one of the most valuable investments we can make is in diversity and inclusion. That’s … Continue reading adMare Communique

adMare BioInnovations Welcomes the First Quebec Start-Ups in its Accelerate Program

December 10, 2020
adMare BioInnovations

adMare today unveiled the six companies selected under its new acceleration program supported by the Quebec Government and the City of Montreal. Montreal, QC – December 10, 2020 – adMare BioInnovations, Canada’s global life sciences venture, is proud to announce the start-ups selected to join its new acceleration program for Quebec emerging companies. The Accelerate … Continue reading adMare BioInnovations Welcomes the First Quebec Start-Ups in its Accelerate Program